Bryan Giraudo Sells 6,000 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Director Bryan Giraudo sold 6,000 shares of the company’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $100.00, for a total value of $600,000.00. Following the completion of the sale, the director owned 31,825 shares of the company’s stock, valued at $3,182,500. This represents a 15.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Bryan Giraudo also recently made the following trade(s):

• On Friday, May 8th, Bryan Giraudo sold 5,130 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $100.00, for a total transaction of $513,000.00.
• On Thursday, May 7th, Bryan Giraudo sold 12,000 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $100.07, for a total transaction of $1,200,840.00.
• On Thursday, May 7th, Bryan Giraudo sold 36,000 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $100.14, for a total value of $3,605,040.00.

Protagonist Therapeutics Stock Performance

PTGX traded up $4.14 on Monday, hitting $103.50. The company had a trading volume of 572,030 shares, compared to its average volume of 669,567. The stock has a market capitalization of $6.66 billion, a price-to-earnings ratio of -57.18 and a beta of 1.89. The stock has a fifty day moving average price of $99.95 and a 200-day moving average price of $89.78. Protagonist Therapeutics, Inc. has a 12-month low of $43.20 and a 12-month high of $107.84.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Tuesday, May 5th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.55. Protagonist Therapeutics had a negative net margin of 154.88% and a negative return on equity of 17.76%. The company had revenue of $56.37 million during the quarter, compared to the consensus estimate of $11.70 million. Analysts forecast that Protagonist Therapeutics, Inc. will post 2.32 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Farallon Capital Management LLC boosted its stake in shares of Protagonist Therapeutics by 0.4% in the third quarter. Farallon Capital Management LLC now owns 6,196,006 shares of the company’s stock worth $411,601,000 after buying an additional 24,000 shares during the last quarter. Jennison Associates LLC purchased a new position in Protagonist Therapeutics in the fourth quarter valued at $28,924,000. SG Americas Securities LLC raised its position in shares of Protagonist Therapeutics by 2,043.8% in the third quarter. SG Americas Securities LLC now owns 41,246 shares of the company’s stock worth $2,740,000 after acquiring an additional 39,322 shares during the period. Mangrove Partners IM LLC boosted its stake in shares of Protagonist Therapeutics by 21.0% during the 3rd quarter. Mangrove Partners IM LLC now owns 478,413 shares of the company’s stock worth $31,781,000 after acquiring an additional 83,030 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH grew its position in shares of Protagonist Therapeutics by 123.1% during the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 90,317 shares of the company’s stock valued at $6,000,000 after acquiring an additional 49,833 shares during the period. 98.63% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have commented on PTGX shares. Wall Street Zen upgraded Protagonist Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Saturday. Wedbush lifted their target price on shares of Protagonist Therapeutics from $112.00 to $118.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Johnson Rice reaffirmed a “buy” rating on shares of Protagonist Therapeutics in a report on Wednesday, March 18th. Barclays boosted their price objective on shares of Protagonist Therapeutics from $113.00 to $119.00 and gave the company an “overweight” rating in a report on Thursday, March 19th. Finally, Citizens Jmp boosted their price target on Protagonist Therapeutics from $120.00 to $137.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 6th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $113.69.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.